Skip to main content

Table 1 Characteristics of the 8 patients with CHH treated by rhLH and rh FSH infusion

From: Growth and descent of the testes in infants with hypogonadotropic hypogonadism receiving subcutaneous gonadotropin infusion

Patients Classification Age at onset of treatment (months) Before treatment After treatment
    Testes position Penile length (mm) Time to descent (months) Testes volume (ml) Testes position Penile length (mm) Duration of treatment (months)
P1 CPHD 6 Non palpable 18 1 0.61 High scrotal 30 6
P2 CPHD 11 Non palpable 20 4 2 Intra-scrotal 33 6
P3 CPHD 10 High-scrotal 30 1 2,1 Intra-scrotal 70 6
P4 IHH 4.5 Non palpable 21 4 0.76 Intra-scrotal 30 6.5
P5 IHH 2.5 Non palpable 20 6 0.7 High-scrotal Intra-scrotal 35 6.5
P6 IHH 9 Non palpable 19 4 1,16 Intra-scrotal 40 5
P7 IHH 5 High-scrotal 28 4 0,89 Intra-scrotal 52 5
P8 IHH 0.25 High-scrotal 13 5 1,95 Intra-scrotal 30 6
  1. IHH isolated hypogonadotropic hypogonadism, CPHD Combined Pituitary Hormonal Deficits (CPHD)